Comparative Efficacy of Biologic Agents in the Treatment of Moderate to Severe Psoriasis
Keywords:
Psoriasis, Biologic Agents, Comparative EfficacyAbstract
Background: Moderate to severe psoriasis significantly impairs quality of life and requires effective systemic therapies. Biologic agents targeting different immune pathways have transformed treatment but comparative efficacy data are limited.
Aim: To compare the efficacy, safety, and quality of life outcomes of Secukinumab, Adalimumab, and Ustekinumab in patients with moderate to severe psoriasis.
Methods: An observational study including 60 patients treated with Secukinumab (n=21), Adalimumab (n=19), or Ustekinumab (n=20) was conducted over 24 weeks. Baseline demographics, Psoriasis Area and Severity Index (PASI), body surface area (BSA), and Dermatology Life Quality Index (DLQI) were recorded. Clinical response was assessed by PASI 75 achievement, time to response, and safety profiles were monitored. Quality of life was evaluated by DLQI score changes.
Results: All biologics demonstrated significant clinical efficacy with PASI 75 rates of 71.4%, 57.9%, and 80.0% for Secukinumab, Adalimumab, and Ustekinumab, respectively (p=0.31). Time to PASI 75 was significantly shorter with Secukinumab and Ustekinumab (p=0.05). Adverse event rates were comparable across groups. Quality of life improvement was significantly greater with Secukinumab and Ustekinumab compared to Adalimumab (p=0.003).
Conclusion: Secukinumab and Ustekinumab showed trends towards faster and greater clinical and quality of life improvements compared to Adalimumab, with all agents maintaining favorable safety profiles. These findings support the use of IL-17 and IL-12/23 inhibitors as effective options in moderate to severe psoriasis
Downloads
Metrics
References
Strober BE, Bissonnette R, Fiorentino D, Kimball AB, Naldi L, Shear NH, Goyal K, Fakharzadeh S, Calabro S, Langholff W, You Y. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). Journal of the American Academy of Dermatology. 2016 May 1;74(5):851-61.
Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao Y, Puig L, Augustin M. Comparative efficacy and relative ranking of biologics and oral therapies for moderate-to-severe plaque psoriasis: a network meta-analysis. Dermatology and therapy. 2021 Jun;11(3):885-905.
Puig L, Lopez A, Vilarrasa E, Garcia I. Efficacy of biologics in the treatment of moderate‐to‐severe plaque psoriasis: a systematic review and meta‐analysis of randomized controlled trials with different time points. Journal of the European Academy of Dermatology and Venereology. 2014 Dec;28(12):1633-53.
Geng W, Zhao J, Fu J, Zhang H, Qiao S. Efficacy of several biological therapies for treating moderate to severe psoriasis: A network meta analysis. Experimental and therapeutic medicine. 2018 Dec 1;16(6):5085-95.
Wu JJ, Feldman SR, Rastogi S, Menges B, Lingohr-Smith M, Lin J. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States. Journal of Dermatological Treatment. 2018 Nov 17;29(8):769-74.
Signorovitch JE, Betts KA, Yan YS, LeReun C, Sundaram M, Wu EQ, Mulani P. Comparative efficacy of biological treatments for moderate‐to‐severe psoriasis: a network meta‐analysis adjusting for cross‐trial differences in reference arm response. British journal of dermatology. 2015 Feb 1;172(2):504-12.
Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, Betts KA, Augustin M. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA dermatology. 2020 Mar 1;156(3):258-69.
Egeberg A, Ottosen MB, Gniadecki R, Broesby‐Olsen S, Dam TN, Bryld LE, Rasmussen MK, Skov L. Safety, efficacy and drug survival of biologics and biosimilars for moderate‐to‐severe plaque psoriasis. British Journal of Dermatology. 2018 Feb 1;178(2):509-19.
Bronckers IM, Paller AS, West DP, Lara-Corrales I, Tollefson MM, Tom WL, Hogeling M, Belazarian L, Zachariae C, Mahé E, Siegfried E. A comparison of psoriasis severity in pediatric patients treated with methotrexate vs biologic agents. JAMA dermatology. 2020 Apr 1;156(4):384-92.
Mahil SK, Ezejimofor MC, Exton LS, Manounah L, Burden AD, Coates LC, De Brito M, McGuire A, Murphy R, Owen CM, Parslew R. Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta‐analysis. British Journal of Dermatology. 2020 Oct 1;183(4):638-49.
Schmitt J, Rosumeck S, Thomaschewski G, Sporbeck B, Haufe E, Nast A. Efficacy and safety of systemic treatments for moderate‐to‐severe psoriasis: meta‐analysis of randomized controlled trials. British Journal of Dermatology. 2014 Feb 1;170(2):274-303.
Iskandar IY, Ashcroft DM, Warren RB, Lunt M, McElhone K, Smith CH, Reynolds NJ, Griffiths CE. Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis. British Journal of Dermatology. 2017 Nov 1;177(5):1410-21.
Singh S, Murad MH, Fumery M, Sedano R, Jairath V, Panaccione R, Sandborn WJ, Ma C. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. The Lancet Gastroenterology & Hepatology. 2021 Dec 1;6(12):1002-14.
Sawyer L, Fotheringham I, Wright E, Yasmeen N, Gibbons C, Holmen Møller A. The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis. Journal of Dermatological Treatment. 2018 Aug 18;29(6):557-68.
Ighani A, Partridge AC, Shear NH, Lynde C, Gulliver WP, Sibbald C, Fleming P. Comparison of management guidelines for moderate-to-severe plaque psoriasis: a review of phototherapy, systemic therapies, and biologic agents. Journal of Cutaneous Medicine and Surgery. 2019 Mar;23(2):204-21.
Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA. Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. Journal of the American Academy of Dermatology. 2018 Jul 1;79(1):135-44.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
